logo
Loading...
Open Access Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
Medicine and HealthBMC Cancer

Open Access Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Y. Harada, A. Sato, et al.

This cutting-edge research by Yohei Harada and colleagues reveals the remarkable efficacy of afatinib, a dual inhibitor of HER2 and EGFR, against cancer models featuring the HER2 E401G mutation. Afatinib significantly outperformed traditional treatments, hinting at its potential as a game-changer for patients with this specific mutation.... show more
Introduction
Literature Review
Methodology
Key Findings
Discussion
Conclusion
Limitations
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 22+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny